Results of Searches and Screening of Potentially Relevant Studies

Slides:

Advertisements

Similar presentations

What the papers say! Exploring the myths of the media

Advertisements

Department of Health and Human Services Center for Drug Evaluation and Research Review of Epidemiologic Studies on Cardiovascular Risk with Selected NSAIDs.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen.

NSAIDS in the ischaemic heart disease patient

Canadian Cardiovascular Society Antiplatelet Guidelines

James Cross, MS Pharmaceutical Outcomes Research and Policy Program University of Washington Biobehavioral Cancer Fellows Day April 20, 2007 A risk-benefit.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Use of Analgesics Most commonly used medications in the US by survey data –#1: acetaminophen –#2: ibuprofen –#3: aspirin – 50% of users on for cardiovascular.

An epidemiologic perspective on etoricoxib David J. Graham, MD, MPH Office of Surveillance and Epidemiology April 12, 2007.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Advisory Committee Presentation on Vioxx (Rofecoxib) Discussion on the meta analyses for cardiovascular risk assessment Qian Li, Sc. D.

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.

Cardiovascular Health Research Unit, Seattle, WA IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD.

Summary Pattern of Specific COX II Inhibitors Use Physician prescribed appropriate COX II use in high risk was 40.08% and inappropriate COX II use in low.

NDAs /772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products.

NSAIDs: Risk of acute MI compared with remote use Largest NSAID database study ever casts doubt on entire coxib controvers [Rheumawire > News; Jun 10,

What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.

Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial Glenn M. Eisen, M.D., M.P.H. Associate.

Cox-2 vs.Other NSAID Use in Children with JRA Data from a cohort study, Beth Gottlieb, MD, Asst. Professor of Pediatrics, Schneider Children’s Hospital,

Hot Topic Presentation Lars Halford, GP ST3 March 2010

基督再來（一）. 經文： 1 你們心裡不要憂愁；你們信神，也當信我。 2 在我父的家裡有許多住處；若是沒有，我就早已告訴你們了。我去原是為你們預備地去。 3 我若去為你們預備了地方，就必再來接你們到我那裡去，我在那裡，叫你們也在那裡， ] ( 約 14 ： 1-3)

NSAIDS NOTES and Tables

NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.

LDR 531 Week 3 Summary R-531/LDR-531-Week-3-Summary For more details

Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.

Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Copyright © 2000 American Medical Association. All rights reserved.

Copyright © 2011 American Medical Association. All rights reserved.

Chronic Kidney Disease in Diabetes

Therapeutics Initiative Drug Assessment Working Group

Copyright © 2014 American Medical Association. All rights reserved.

HS4160 Critical Scientific Analysis

Tips Need to Consider When Organizing a College Event

Selection of NSAIDs for Osteoarthritis

Nurses' Health Study: Risk of hypertension associated with >1000 µg/day of folate vs

Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis

Volume 120, Issue 3, Pages (February 2001)

Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.

Douglas K Rex, MD, FACG Journal of Pain and Symptom Management

David J.A. Jenkins et al. JACC 2018;71:

Pharmacoeconomics of Coxib Therapy

NSAIDs: Risk of acute MI compared with remote use

Update on NSAID Use:.

Drug used within 3 months of index date Adjusted odds ratio* p

ماجستير إدارة المعارض من بريطانيا

US Preventive Services Task Force. Ann Intern Med 2009;150:

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Слайд-дәріс Қарағанды мемлекеттік техникалық университеті

Avoiding Opioid Overuse: Guideline-Based Management of Osteoarthritis

OTC NSAID Use in Patients With OA and CV Disease

.. -"""--..J '. / /I/I =---=-- -, _ --, _ = :;:.

Volume 387, Issue 10033, Pages (May 2016)

Relative risk of major events with atenolol vs placebo

Jun M, et al. Lancet 2010 Epub May 10

Coxibs—Beyond the GI Tract

II //II // \ Others Q.

I1I1 a 1·1,.,.,,I.,,I · I 1··n I J,-·

Trial Selection Process

Number of patients who received at least one prescription for a COX-2 inhibitor or NSAID after hospital discharge Drug Patients % of study cohort Rofecoxib.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

Treating Osteoarthritis

Berger JS, et al. JAMA 2009;301:

Emerging Risk Factors Collaboration. JAMA 2009;302:412-23

Flow chart of search strategy

. '. '. I;.,, - - "!' - -·-·,Ii '.....,,......, -,

For More Details:

Relative risks of colon cancer in prospective cohort studies, comparing the highest with the lowest category of heme iron consumption. Relative risks of.

Presentation transcript:

Results of Searches and Screening of Potentially Relevant Studies Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644

Details of the Case-Control Studies Included in the Meta-analysis - Part I Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644

Details of the Case-Control Studies Included in the Meta-analysis - Part II Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644

Details of the Cohort Studies Included in the Meta-analysis Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644

Results of Case-Control and Cohort Studies Reporting on Cardiovascular Risks With Cyclooxygenase 2 Inhibitors Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644

Results of Case-Control and Cohort Studies Reporting on Cardiovascular Risks With Nonselective NSAIDs Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644

Point Estimates and Summary Relative Risks for Cardiovascular Events With Rofecoxib and Celecoxib Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644

Point Estimates and Summary Relative Risks for Cardiovascular Events With Naproxen and Diclofenac Patricia McGettigan, and David Henry. JAMA 2006;296:1633-1644